Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.32 |
| ▸ | BUB1 | O43683 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6487098 | 1.00 | NISCH (0.32) | NISCHBUB1MAPTALDH1A1HTT | |
| SCHEMBL6487310 | 0.88 | ALDH1A1 (0.33) | BUB1MAPTALDH1A1HTTKDM4E | |
| SCHEMBL6486879 | 0.84 | MAPT (0.38) | NISCHMAPTALDH1A1HTTADRA2A | |
| SCHEMBL6489930 | 0.79 | HPGD (0.33) | ALDH1A1HTTADRA2AADRA2BADRA2C | |
| SCHEMBL6489927 | 0.79 | HPGD (0.33) | ALDH1A1HTTADRA2AADRA2BADRA2C | |
| SCHEMBL6487105 | 0.78 | HTR1D (0.38) | NISCHBUB1MAPTADRA2AADRA2B | |
| SCHEMBL6496897 | 0.73 | HTR2A (0.37) | NISCHMAPTALDH1A1HTT | |
| SCHEMBL6496901 | 0.73 | HTR2A (0.37) | NISCHMAPTALDH1A1HTT | |
| SCHEMBL6497443 | 0.72 | MAP3K14 (0.40) | MAPTALDH1A1HTTHTR1B | |
| SCHEMBL6488757 | 0.72 | MAP3K14 (0.40) | MAPTALDH1A1HTTHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951881-B2 | (1-substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-10-04 | — | — | US | disclosed |
| US-20030232843-A1 | (1-Substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232843-A1 | (1-Substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | NISCH 1057/4885BUB1 2706/4885MAPT 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.